


1636




FULBRIGHT & JAWORSKI L.L.P.
 A REGISTERED LIMITED LIABILITY PARTNERSHIP
 600 CONGRESS AVENUE, SUITE 2400
 AUSTIN, TEXAS 78701-3271
 WWW.FULBRIGHT.COM

SHIGHLANDER@FULBRIGHT.COM
 PARTNER
 DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201
 FACSIMILE: (512) 536-4598

April 15, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
<u>April 15, 2004</u> Date	 Steven L. Highlander

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450


Re: Serial Number 09/612,809 entitled "THERAPEUTICS AND DIAGNOSTICS FOR CONGENITAL HEART DISEASE BASED ON A NOVEL HUMAN TRANSCRIPTION FACTOR" by Val C. Sheffield
Our ref: IOWA:042USD1

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Resubmitted Amendment and Request for Reconsideration Under 37 C.F.R. §1.111;
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/IOWA:042USD1/SLH.

Very truly yours,

 Steven L. Highlander

SLH/cpj

Encl: As noted


25405742.1



CERTIFICATE OF MAILING
37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450; Alexandria, VA 22313-01450, on the date below:

April 15, 2004
Date


Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Val. C. SHEFFIELD *et al.*

Serial No.: 09/612,809

Filed: July 10, 2000

For: THERAPEUTICS AND DIAGNOSTICS
FOR CONGENITAL HEART DISEASE
BASED ON A NOVEL HUMAN
TRANSCRIPTION FACTOR

Group Art Unit: 1636

Examiner: LEFFERS, G.

Atty. Dkt. No.: IOWA:042USD1/SLH

**RESUBMITTED AMENDMENT AND REQUEST FOR
RECONSIDERATION UNDER 37 C.F.R. §1.111**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-01450

Dear Sir:

This paper is submitted in response to the Office Communication dated March 23, 2004, to which a response is due on April 23, 2004. It is believed that no fees are due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/IOWA:042USD1/SLH.

Amendments start on page 2 of this response.

Remarks start on page 5 of this response.